Skip to content

Impact of Heart Rate Variability Modulation on Stress Management Among Physicians

Impact of Heart Rate Variability Modulation on Stress and Recovery Among Physicians

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05731856
Enrollment
50
Registered
2023-02-16
Start date
2024-01-15
Completion date
2027-11-01
Last updated
2026-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burnout, Professional

Brief summary

The purpose of this research is to examine a wearable device called Apollo that emits gentle vibrations found to benefit mood, energy, and focus. We want to understand how it affects burnout in physicians.

Detailed description

This study will be conducted by using a Tuned Vibroacoustic Stimulation (TVS) device(the commercially available TVS device known as the Apollo wearable), that has been shown in clinical studies at University of Pittsburgh to improve heart rate variability and recovery under stress. The Apollo wearable generates low volume sound waves that feel like a soothing touch to the skin. This study will assess whether slight modulation of heart rate variability (HRV) will result in a reduction in stress, improved recovery, and recovery in and around the hospital. Physicians will wear the Apollo device for heart rate variability modulation and complete questionnaires before and after use of the Apollo device for comparison of outcomes.

Interventions

Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phones. Participants will use the Apollo for at least 30 minutes after waking up and at least 30 minutes before bed on the corresponding settings for those times of the day. They will be given the Apollo Device TVS (10-200 Hz) to borrow, which they will be instructed to wear daily. They will be asked to wear the device until all study data is collected.

Sponsors

Michelle Thompson
Lead SponsorOTHER
The Board of Medicine
CollaboratorOTHER
Apollo Neuroscience, Inc.
CollaboratorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

This is a single group study. All participants will receive identical instructions regarding the device and will complete the same survey measures.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* UPMC attending physicians and residents. The participants must have either IOS or Android phones.

Exclusion criteria

* Unwillingness or inability to participate in the study * Currently own an Apollo device

Design outcomes

Primary

MeasureTime frameDescription
Copenhagen Burnout InventoryThrough study completion, on average 8 weeksThe Copenhagen Burnout Inventory (CBI) is a 19-item self reported measure of burnout. It contains three sub-scales measuring personal burnout, work-related burnout, and client-related burnout
Perceived Stress Scale (PSS-10)Through study completion, on average 8 weeksThe Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress using a 10-item survey. It is a measure of the degree to which situations in one's life are appraised as stressful.

Secondary

MeasureTime frameDescription
The Quick Inventory of Depressive SymptomatologyThrough study completion, on average 8 weeksThe QIDS is a brief, 16-item self-rated assessment tool used to evaluate the symptoms of depression present in a patient during the past week.
Pittsburgh Sleep Quality Index (PSQI)Through study completion, on average 8 weeksThe Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. With a range of scores 1-21.

Countries

United States

Contacts

CONTACTFranchesca Inay, BS
inay.franchesca@medstudent.pitt.edu5512234990
CONTACTMahi Mandala, PhD
mahi@apolloneuro.com4129450345
PRINCIPAL_INVESTIGATORMichelle Thompson, DO

University of Pittsburgh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026